---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-018713"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T14:51:55.648369+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports $424M cash; ziftomenib combo achieves 100% CR in newly diagnosed AML

## Summary
- Preliminary unaudited cash $424M as of Dec 31, 2023; net proceeds from private placement $146M.
- Phase 1 KOMET-007: 5 newly diagnosed patients on ziftomenib+7+3 all achieved CR (100%).
- R/R patients on ziftomenib+ven/aza: ORR 53% (8/15); CR/CRh 56% in menin inhibitor-naïve.
- No differentiation syndrome, QTc prolongation, or DLTs observed; well-tolerated.
- Expects to complete KOMET-001 enrollment by mid-2024; cash runway into 2027.

## SEC filing metadata
- accession: 0001193125-24-018713
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312524018713/0001193125-24-018713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312524018713/d686268d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-018713
- JSON: https://secwatch.observer/filing/0001193125-24-018713.json
- Plain text: https://secwatch.observer/filing/0001193125-24-018713.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.